Publications by authors named "G L Hantsbarger"
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFArticle Synopsis
- Patients with Crohn's disease who also have perianal fistulas face additional complications like fecal incontinence, pain, and a higher treatment burden compared to those without these fistulas.
- A study involved 929 patients across three cohorts to assess their quality of life and treatment preferences using validated questionnaires and a discrete choice experiment.
- Results showed that patients with perianal fistulas experienced worse quality of life scores, and treatment choices were largely influenced by factors such as postoperative discomfort and the rate of fistula healing.
Background: Crohn's-related rectovaginal fistulas (RVF) greatly impact quality of life and are notoriously difficult to treat. The aim of this study was to assess the burden of recurrent episodes of care for RVF and its economic impact.
Methods: A retrospective observational cohort study of administrative US claims databases was conducted.
Background: The efficacy of a single administration of darvadstrocel (expanded allogeneic adipose-derived mesenchymal stem cells) for treating complex perianal fistulas in patients with Crohn's disease was demonstrated in a randomized, double-blind trial (ADMIRE-CD [Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn\'s Disease] trial). The current chart review study (INSPECT [A retrospectIve chart review study evaluatINg the longer-term effectiveneSs of darvadstrocel in PatiEnts who CompleTed ADMIRE-CD]) evaluated the longer-term effectiveness and safety of darvadstrocel.
Methods: Eligible patients had completed at least 52 weeks in the ADMIRE-CD trial.
Background: Vedolizumab is a gut-selective antibody to α β integrin approved to treat moderate-to-severe Crohn's disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and immunosuppressant use are associated with increased risk of malignancy.
Aim: To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI long-term safety (LTS) study and post-marketing (PM) setting.